XDATA – August 29th 2014
Nanospectra Biosciences sold a total of $800,000 in a non-brokered equity investment round. The transaction which started a week ago, garnered the support of fifteen investors. A total of six unregistered securities offerings closed by the company raised an estimated $7.9 million.
The company is focused on the development of AuroLase therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The AuroLase therapy process involves infusing a single dose of nanoshell particles into the patient’s blood stream via intravenous injection. After 12 to 24 hours, enough time for the particles to accumulate inside the tumor, a special laser is used to illuminate and heat the particles within the tumor.
The company, headquartered in Houston TX, is led by David Jorden (CEO). Nanospectra Biosciences elected to keep its revenues undisclosed.
The executive team includes Glenn Goodrich and Patrick Pace.
The board of directors includes Bradley Nyberg, David Bristol and Jennifer West.
The company has raised an estimated total of $8.7 million via private unregistered security offerings.
Company: Nanospectra Biosciences
Industry: Other Health Care
Amount offered: $800,000
Amount placed: $800,000
First sale: 08-22-2014
Data as of: 08-29-2014
XDATA – August 29th 2014
33% of Gusto‘s $1.5 million unregistered private offering was placed on August 12th. The non-brokered equity securities were subscribed by three investors. The first close garnered $500,000. The offering will remain open until August 2015 while an additional $1 million worth of securities is sold to investors. This is the first time Gusto is selling securities under a registration exemption.
Gusto develops and markets a mobile application for e-mail visualization and attachments download. The app saves all files and photos users sent or received in a single place, automatically, across all email accounts.
Shawn Schwegman (CEO) leads the Indianapolis IN based company which was registered in 2012. Gusto elected to keep its revenues undisclosed.
The board of directors includes Gerald J Longa, Jason Kellerman, Peter K Hawryluk and Ting Gootee.
Status: First close
Industry: Other Technology
Amount offered: $1.5 million
Amount placed: $500,000
First sale: 08-12-2014
Data as of: 08-27-2014
XDATA – August 29th 2014
Enviro Water Minerals sold a total of $3 million in a non-brokered equity investment round. The transaction which started two days ago, garnered the support of fifteen investors. Until this disclosure Enviro Water Minerals had raised an estimated $2 million in unregistered securities via one previous financing round.
Enviro Water Minerals commercializes a technology to recover the minerals discharged in wastewater from brackish water desalination plants. It uses proven and commercially available technologies in innovative configurations to chemically separate the wastewater into industrial-grade mineral products as well as producing potable water.
Hubble Hausman (CEO) leads the Houston TX based company which was registered in 2012. No revenues were reported by the company.
The executive team includes Joseph Hubble Hausman.
The board of directors includes Carey Paul Hausman, Lane Richard Brostrom and Tommy Wayne Lott.
The company has raised an estimated total of $5 million via private unregistered security offerings.
Company: Enviro Water Minerals
Amount offered: $3 million
Amount placed: $3 million
First sale: 08-27-2014
Data as of: 08-29-2014
XDATA – August 28th 2014
Earnest Research Co sold a total of $3.5 million in a non-brokered equity investment round. The transaction which started on August 14th, garnered the support of fifteen investors. Until this disclosure Earnest Research Co had raised an estimated $800,000 in unregistered securities via one previous financing round.
Earnest Research Co develops a big data trend analysis and predictive platform designed to help companies grasp consumer trends.
The company, headquartered in New York NY, is led by Kevin Carson (CEO). Earnest Research Co elected to keep its revenues undisclosed.
The executive team includes Kevin Alexander Carson.
The board of directors includes Jason Douglas Mcdougall and John Elton.
The company has raised an estimated total of $4.3 million via private unregistered security offerings.
Company: Earnest Research Co
Amount offered: $3.5 million
Amount placed: $3.5 million
First sale: 08-14-2014
Data as of: 08-28-2014
tengrade, Inc. completed a partial close of its $1 million equity offering, placing 57% of the total amount with 10 investors. The company is looking for at most thirty additional investors for the placement which will remain open for a year. This is the first known non-brokered US private placement initiated by the company.
The company developed a platform which aims to become the world’s central repository for popularity ratings. Users can rate on a scale from 1 to 10 anything they are interested in and share and compare their opinion with their friends and connections. tengrade created a visualization tool called the the “tornado” which allow viewers to instantly assess likes and dislikes of the world, their connections as a group or as individuals and of course their own.
tengrade, headquartered in New York City, was founded in April 2010 by Stuart Strumwasser (President) and Ted Werth (CEO). The company was originally founded as tengrade LLC and was merged out into tengrade, Inc. at the beginning of the month.
CivaTech Oncology, Inc. raised $400,000 from one investor via a non-brokered private equity placement. Civatech has offered an estimated $5 million since August 2006, 27% of which was for debt and mezzanine securities. Investors Management Corp. (IMC), a Raleigh based family office, is among the financial backers of the company.
The company develops and markets polymer based medical devices to simplify and increase the effectiveness of low-dose-rate brachytherapy treatments. Brachytherapy is known as internal radiotherapy or sealed source radiotherapy, where radioactive “seeds” are inserted in the patient’s body. The company’s patented and patent-pending technology enables devices that can be designed and fabricated for specific tumor types. CivaString, the first product, has been granted FDA 510k clearance to treat any solid tumor. Further details on patents can be found at the US Patent and Trademark Office.
CivaTech, headquartered in Research Triangle Park NC, was founded in April 2006 by founder Suzanne Troxler Babcock (Chairman and CEO).
SonicSurg Innovations LLC is in the market placing $1 million worth of equity via a non-brokered offering. The company is looking for at most forty investors. A similar equity offering was successfully completed in 2011 raising nearly $1 million in less than five months. $100,000 of the proceeds have been earmarked to be paid toward finder’s fee and $130,000 will be allocated to general and administrative expenses.
SonicSurg develops and commercializes products for the orthopaedic upper-extremity surgical market. Its current product “Trigger Tome” is a medical device designed to perform an office-based and minimally invasive surgical procedure for “stenosing tenosynovitis” a condition commonly known as “trigger finger”.
The company, located in Lakeland, FL, was founded in August 2009 by Brian M. Jurbala a board certified orthopaedic surgeon. In addition the team includes: James S. Phillips (President) and Joel S. Norenberg (VP – sales & marketing).
Applied Bioresearch, Inc., raised 10% of its expected $500,000 non-brokered equity offering. This financing brings to $300,000 the estimated amount raised via private placement equity issuance by the company. Applied Bioresearch is looking for another eighteen investors at most.
While the product developed by the company is not known at this time, it is related to the pharmaceutical industry. The company is an affiliate of World Health Products LLC, a company which developed and markets Detoxamin, a suppository for chelation therapy. Chelation therapy involves the removal of heavy metals and other materials from the body. The company also markets a host of dietary, nutritional supplements and other wellness related products.
Applied Bioresearch, headquartered in Draper, UT., was founded in June 2011 by Kendal E. Svedeen.
Greenleaf Juicing Company, LLC raised $200,000 in equity from one investor. This brings the estimated amount raised to $260,000 via debt and equity issuance. No placement agent was used in conjunction with the financing events.
The company offers an extensive menu of juices, smoothies and soups made with fresh, organic fruits and vegetables sourced locally whenever available. The company has currently two locations in Portland, OR. Each juice contains two pounds of fresh fruit and vegetables nothing more. Juices cost $5.95 while soups go for $6.50. The company recently started to sell fresh cold pressed juices in 16oz bottles that last up to 72 hours.
Greenleaf, is located in Portland, OR and was founded in April 2011 by Garret Flynn and Matthew Trenkle.
Aviacomm Inc., raised $500,000 in a direct equity offering. The offering was placed with one investor.
The company develops next generation radio frequency integrated circuit (RFIC) capable of overcoming current RFIC restrictions such as limited spectral coverage and restricted channelization. The goal is to support multiple protocols and technologies up and down the frequency spectrum. The company’s complementary metal–oxide–semiconductor (CMOS) RFIC, called ARF1010EX, covers 300MHz to 2.85GHz and channels sizes from 0.5MHz to 40MHz.
Aviacomm is located in San Jose, CA, and was founded by Shih H. Mo (CEO) in August 2009. Other executives include: Dr. Hans Wang (VP Engineering), Chenyu Chang (COO) and Dave Sumi (VP Product Marketing).